XML 45 R33.htm IDEA: XBRL DOCUMENT v3.26.1
Revenues (Tables)
 3 Months Ended
Mar. 31, 2026
Revenue from Contract with Customer [Abstract]  
Schedule of Product Revenue The table below presents the Company’s gross and net product revenue ($ in thousands):
Three Months Ended March 31,
20262025
Product revenue - gross102,254 112,333 
Less: Rebates and sales returns(6,698)(6,683)
Product revenue - net95,556 105,650 
Schedule of Disaggregation of Net Revenue
The following table presents the Company’s net revenue by commercial program ($ in thousands):
Three Months Ended March 31,
20262025
ZEJULA29,967 49,529 
VYVGART / VYVGART Hytrulo17,551 18,105 
NUZYRA16,262 15,118 
OPTUNE12,070 11,363 
QINLOCK8,985 8,509 
XACDURO8,572 1,117 
AUGTYRO1,792 1,626 
Other (i)357 283 
Product revenue - net95,556 105,650 
(i)Other includes product candidates sold in patient programs prior to commercialization.